Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-7 of 7
Keywords: Medroxyprogesterone Acetate
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
No Effect of High-Dose Medroxyprogesterone Acetate on the Frequency of Sister Chromatid Exchange in Lymphocytes of Cancer Patients
Available to PurchaseSubject Area:
Oncology
Journal:
Oncology
Oncology (1988) 45 (1): 57–60.
Published Online: 25 June 2009
...Reinhard Becher Sister chromatid exchange observed in metaphase chromosomes has been shown to be a sensitive assay for the detection of possible mutagenic and/or carcinogenic agents. The semisynthetic progestin medroxyprogesterone acetate is a drug used in high doses for the treatment of advanced...
Journal Articles
Oral High-Dose Medroxyprogesterone Acetate (MPA) Treatment: Cortisol/MPA Serum Profiles in Relation to Breast Cancer Regression
Available to PurchaseSubject Area:
Oncology
Journal:
Oncology
Oncology (1985) 42 (3): 144–149.
Published Online: 17 June 2009
...M. Mahlke; H.-J. Grill; P. Knapstein; U. Wiegand; K. Pollow Medroxyprogesterone acetate (MPA), a potent synthetic progestin, has been widely used in the hormonal treatment of advanced breast cancer, but presently with varying dose schedules. The availability of a sensitive RIA-method...
Journal Articles
Paradoxical Hormone Responses of KPL-1 Breast Cancer Cells in vivo: A Significant Role of Angiogenesis in Tumor Growth
Available to PurchaseSubject Area:
Oncology
Junichi Kurebayashi, Hironori Kunisue, Shigeru Yamamoto, Masafumi Kurosumi, Takemi Otsuki, Hiroshi Sonoo
Journal:
Oncology
Oncology (2000) 59 (2): 158–165.
Published Online: 25 August 2000
.... To investigate the action mechanisms of these paradoxical responses, the effects of E2, ovariectomy (Ovex) and medroxyprogesterone acetate (MPA) on the growth, angiogenesis, apoptosis and expression of vascular endothelial growth factor (VEGF) were investigated. E2 stimulated the growth of KPL-1 cells but MPA...
Journal Articles
An Analysis of Serum Interleukin-6 Levels to Predict Benefits of Medroxyprogesterone Acetate in Advanced or Recurrent Breast Cancer
Available to PurchaseSubject Area:
Oncology
Reiki Nishimura, Kazuharu Nagao, Haruhiko Miyayama, Masakazu Matsuda, Kenichirou Baba, Yukio Matsuoka, Hiroya Yamashita, Makoto Fukuda, Takao Mizumoto, Rieko Hamamoto
Journal:
Oncology
Oncology (2000) 59 (2): 166–173.
Published Online: 25 August 2000
...Reiki Nishimura; Kazuharu Nagao; Haruhiko Miyayama; Masakazu Matsuda; Kenichirou Baba; Yukio Matsuoka; Hiroya Yamashita; Makoto Fukuda; Takao Mizumoto; Rieko Hamamoto Treatment of advanced or recurrent breast cancer with medroxyprogesterone acetate (MPA) shows high response rates and the accessory...
Journal Articles
A Randomized Controlled Comparative Study of Oral Medroxyprogesterone Acetate 1,200 and 600 mg in Patients with Advanced or Recurrent Breast Cancer
Available to PurchaseSubject Area:
Oncology
Hiroki Koyama, Takeshi Tominaga, Kazuaki Asaishi, Rikiya Abe, Yuichi Iino, Kohji Enomoto, Shigeto Miura, Yasuo Nomura, Hiroaki Nakazato, Osahiko Abe
Journal:
Oncology
Oncology (1999) 56 (4): 283–290.
Published Online: 21 May 1999
...Hiroki Koyama; Takeshi Tominaga; Kazuaki Asaishi; Rikiya Abe; Yuichi Iino; Kohji Enomoto; Shigeto Miura; Yasuo Nomura; Hiroaki Nakazato; Osahiko Abe A randomized controlled comparative study of oral medroxyprogesterone acetate (MPA) 1,200 mg (arm I) and 600 mg (arm II) was conducted in 80 patients...
Journal Articles
Subject Area:
Oncology
Journal:
Oncology
Oncology (1999) 56 (3): 198–201.
Published Online: 08 April 1999
...-fluoruracil (500 mg/m 2 ) given on day 1, in a 3-weekly schedule, in combination with medroxyprogesterone acetate (MPA): 300 mg daily, p.o., until progression (JMF-M regimen). None had received prior chemotherapy and/or hormonotherapy for metastatic disease. Ten patients had received radiotherapy. Response...
Journal Articles
Endocrine Therapy in Pancreatic Carcinoma
Available to PurchaseSubject Area:
Oncology
Journal:
Oncology
Oncology (1998) 55 (Suppl. 1): 17–22.
Published Online: 21 December 1998
... with this lethal cancer may have a potential clinical benefit from endocrine therapy, especially medroxyprogesterone acetate treatment. Endocrine therapy Pancreatic carcinoma Estrogen dependence Tissue plasminogen activator Medroxyprogesterone acetate Oncology 1998;55(suppl 1):17 22 Jun-ichi Yamashita...
